

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number  
**WO 2005/035777 A1**

(51) International Patent Classification<sup>7</sup>: C12P 21/06

Ralph, A. [US/US]; 8538 Nottingham Place, LA JOLLA, California 92037 (US).

(21) International Application Number:

PCT/US2004/033137

(74) Agents: CEPURITIS, Talivaldis? et al.; OLSON & HERL, LTD., 20 North Wacker Drive, 36th Floor, Chicago, Illinois 60606 (US).

(22) International Filing Date: 7 October 2004 (07.10.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/509,457 8 October 2003 (08.10.2003) US

(71) Applicant (for all designated States except US): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, California 92037 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): LUO, Yunping [CN/US]; 9501 Genesee Avenue, #603, San Diego, California 92122 (US). XIANG, Rong [CN/US]; 4226 Camino Ticino, San Diego, California 92122 (US). REISFELD,

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

[Continued on next page]

(54) Title: DNA VACCINES AGAINST TUMOR GROWTH AND METHODS OF USE THEREOF



WO 2005/035777 A1

(57) Abstract: A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated in an attenuated bacterial vector, such as an attenuated *Salmonella typhimurium*, particularly a doubly attenuated aroA-dam- *S. typhimurium*. Transformed host cells, methods of inhibiting tumor growth, of vaccinating a patient against cancer, and of delivering genetic material to a mammalian cell in vivo are also described.

BEST AVAILABLE COPY



FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BEST AVAILABLE COPY